Connection
Katy Trinkley to Treatment Outcome
This is a "connection" page, showing publications Katy Trinkley has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.243 |
|
|
|
-
Derington CG, King JB, Delate T, Botts SR, Kroehl M, Kao DP, Trinkley KE. Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. PLoS One. 2020; 15(12):e0243371.
Score: 0.070
-
Trinkley KE, Sturm AM, Porter K, Nahata MC. Efficacy and Safety of Atypical Antipsychotics for Behavioral and Psychological Symptoms of Dementia Among Community Dwelling Adults. J Pharm Pract. 2020 Feb; 33(1):7-14.
Score: 0.058
-
Tsai T, Kroehl ME, Smith SM, Thompson AM, Dai IY, Trinkley KE. Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension. J Clin Hypertens (Greenwich). 2017 Sep; 19(9):868-873.
Score: 0.055
-
VanderWeide LA, Smith SM, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. J Clin Pharm Ther. 2015 Feb; 40(1):1-6.
Score: 0.046
-
Sturm AS, Trinkley KE, Porter K, Nahata MC. Efficacy and safety of atypical antipsychotics for behavioral symptoms of dementia among patients residing in long-term care. Int J Clin Pharm. 2018 Feb; 40(1):135-142.
Score: 0.014